Damian Clarke-Bruce
Chief Executive Officer presso HaemaLogiX Pty Ltd.
Patrimonio netto: 5 556 $ in data 30/04/2024
Profilo
Damian Clarke-Bruce is currently the Chief Executive Officer & Managing Director at HaemaLogiX Pty Ltd.
He was previously the Chief Executive Officer, MD & Director at Race Oncology Ltd.
and the Executive Director-Global Marketing at Pharming Group NV.
Mr. Clarke-Bruce has an undergraduate degree from The University of New South Wales, a graduate degree from Macquarie University, and a graduate degree from The University of Sydney.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0.00% | 21/08/2023 | 6 818 ( 0.00% ) | 5 556 $ | 30/04/2024 |
Posizioni attive di Damian Clarke-Bruce
| Società | Posizione | Inizio |
|---|---|---|
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Chief Executive Officer | 13/11/2023 |
Precedenti posizioni note di Damian Clarke-Bruce
| Società | Posizione | Fine |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chief Executive Officer | 22/08/2023 |
| PHARMING GROUP N.V. | Sales & Marketing | 01/01/2023 |
Formazione di Damian Clarke-Bruce
| The University of New South Wales | Undergraduate Degree |
| Macquarie University | Graduate Degree |
| The University of Sydney | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PHARMING GROUP N.V. | Health Technology |
| RACE ONCOLOGY LIMITED | Health Technology |
| Aziende private | 1 |
|---|---|
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |
- Borsa valori
- Insiders
- Damian Clarke-Bruce
